AUSTIN, Texas and CAMBRIDGE, Mass., May
23, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ:
GNPX), a clinical stage gene therapy company developing a new
approach to treating cancer based upon a novel proprietary
technology platform, announced today that the management team will
present at the following upcoming investor and industry
conferences:
Event: 2018 BIO International Convention
Date: June 5, 2018
Time: 2:30 PM EDT
Location: Boston, MA
Presenter: Dr. Julien Pham, President and COO
Event: 8th Annual LD Micro Invitational
Date: June 5, 2018
Time: 3:00 PM PDT
Location: Bel-Air, CA
Presenter: Rodney Varner, Chairman and CEO
About Genprex, Inc.
Genprex, Inc. is a clinical stage
gene therapy company developing a new approach to treating cancer,
based upon a novel proprietary technology platform, including
Genprex's initial product candidate, Oncoprex™ immunogene therapy
for non-small cell lung cancer (NSCLC). Genprex's platform
technologies are designed to administer cancer fighting genes by
encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken
up by tumor cells where they express proteins that are missing or
found in low quantities. Oncoprex has a multimodal mechanism of
action whereby it interrupts cell signaling pathways that cause
replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells,
and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug
resistance. Visit the company's web site at www.genprex.com or
follow Genprex on Twitter at https://twitter.com/genprex and
Facebook at https://www.facebook.com/genprexinc/.
Contact:
Media:
James
Heins
ICR
Healthcare
203-682-8251
James.Heins@icrinc.com
|
Investors:
Stephanie
Carrington
ICR
Healthcare
646-277-1282
Stephanie.Carrington@icrinc.com
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/genprex-to-present-at-upcoming-investor-and-industry-conferences-300653628.html
SOURCE Genprex, Inc.